Live virtual fireside chat — investors, advisors, and life sciences analysts invited to attendFeaturing Dermatologist Mary Spellman, M.D., with Phio CEO Robert Bitterman and Force Family Office CEO Steven

<p><b>Live virtual fireside chat &#8212; investors, advisors, and life sciences analysts invited to attend</b></p><p><b>Featuring Dermatologist Mary Spellman, M.D., with Phio CEO Robert Bitterman and Force Family Office CEO Steven Saltzstein</b></p><p>King of Prussia, Pennsylvania--(Newsfile Corp. - May 12, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PHIO">PHIO</a>) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL<sup>&#174;</sup> gene silencing technology to eliminate cancer.  Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Steven Saltzstein, CEO, Force Family Office. Joining them will be Dr. Mary Spellman, Board Certified, licensed dermatologist who will explore both prevention and next-generation treatment strategies for various forms of skin cancer. </p><p>"We are excited to take part in this fireside chat with Force Family Office," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals. "Dr. Spellman will discuss the future direction of dermatologic oncology and highlight how our INTASYL&#174; siRNA program represents a differentiated and innovative approach to immuno-oncology."</p><p><b>DATE:  Tuesday May 19, 2026</b></p><p><b>TIME:   4 PM EDT</b></p><p><b>REGISTRATION LINK:  </b><a href="https://api.newsfilecorp.com/redirect/DOEy8fPKma"><b>PHIO Pharma - Force Family Office</b></a></p><p><b>Recent Company Highlights</b></p><p>Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. In its Phase 1b trial, Phio has reported that 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events. The Company has also reported a pathological response rate in cSCC across all dosing cohorts of approximately 65%, including an 85% pathological response (6 of 7 patients) in the highest-dose cohort.</p><p>Phio has indicated that FDA engagement regarding next-stage clinical development is targeted for the second quarter of 2026 and has reported cash and cash equivalents projected to sustain operations into the first half of 2027.</p><p><b>About Phio Pharmaceuticals Corp.</b></p><p>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PHIO">PHIO</a>) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL<sup>&#174;</sup> siRNA gene silencing technology to eliminate cancer. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.</p><p>For additional information, visit the Company's website, <a href="https://api.newsfilecorp.com/redirect/rpBXzTw1ym" target="_blank">www.phiopharma.com</a>.  </p><p><b>Forward Looking Statements</b></p><p><i>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements, among other things, regarding the anticipated benefits of our INTASYL&#8482; RNAi platform, the results from our ongoing clinical trials, our expectations that our cash runway will extend into the first half of 2027, our expectations regarding timing of FDA submissions intended to propose and seek guidance for next steps in clinical study design for PH-762, our expectations that such FDA submissions and any related FDA meetings will clarify next steps in advancing the PH-762 development program, details regarding our planned non-clinical toxicology study, and our ability to support ongoing clinical development, operational requirements and strategic initiatives with the capital we currently have on hand, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact of future FDA interactions on the development of our product candidates; the impact to our business and operations by inflationary pressures; recession fears; the development of our product candidates, results from our nonclinical, preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the U.S. Securities and Exchange Commission. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.</i></p><div id="contactInfo"><p><b>Contact:<br />Phio Pharmaceuticals Corp.<br /></b>Jennifer Phillips: <a href="mailto:jphillips@phiopharma.com" target="_blank">jphillips@phiopharma.com<br /></a>Corporate Affairs </p></div><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/10407/296886_2219419cc41d6a03_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/VvjrkfMrXD">https://www.newsfilecorp.com/release/296886</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/296886/197" alt="" /></p>

PHIO

Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026

Phio Pharmaceuticals Engages in Key Discussion on Cancer Treatments

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Live virtual fireside chat — investors, advisors, and life sciences analysts invited to attendFeaturing Dermatologist Mary Spellman, M.D., with Phio CEO Robert Bitterman and Force Family Office CEO Steven</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Phio Pharmaceuticals is participating in an upcoming fireside chat aimed at discussing new strategies in dermatologic oncology, notably featuring its lead candidate PH-762. The strong Phase 1b trial results and scheduled FDA interactions could serve as significant catalysts for the company&#039;s stock performance.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Phio Pharmaceuticals participates in a fireside chat on cancer treatment.</li><li>CEO Bitterman and Dr. Spellman discuss the future of dermatologic oncology.</li><li>Phase 1b trial shows promising results for PH-762 in skin cancer treatments.</li><li>Pathological response rate of 65% observed in cSCC across dosing cohorts.</li><li>FDA engagement for next-stage clinical development is targeted for Q2 2026.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Force Family Office (N/A)</strong>: Participating in the fireside chat could attract increasing investor interest.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under &#039;Corporate Developments&#039; due to the strategic nature of the discussion around product development and market positioning. The insights shared could directly influence investor decisions and sentiment regarding Phio&#039;s stock.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Positive dialogue in the upcoming fireside chat could enhance investor sentiment.</li><li>Successful FDA engagement in Q2 2026 may accelerate PH-762&#039;s development timeline.</li><li>Strong clinical trial results could lead to increased analyst upgrades.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>PH-762 showed a 65% pathological response rate in cutting-edge trials.</li><li>85% response in the highest-dose cohort from the Phase 1b study.</li><li>Cash runway expected to sustain operations into the first half of 2027.</li><li>Fireside chat scheduled for May 19, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Invest in PHIO as Phase 1b trials yield positive results and FDA engagement is imminent.</p>
  </section>
</section>


<p><b>Live virtual fireside chat &#8212; investors, advisors, and life sciences analysts invited to attend</b></p><p><b>Featuring Dermatologist Mary Spellman, M.D., with Phio CEO Robert Bitterman and Force Family Office CEO Steven Saltzstein</b></p><p>King of Prussia, Pennsylvania--(Newsfile Corp. - May 12, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PHIO">PHIO</a>) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL<sup>&#174;</sup> gene silencing technology to eliminate cancer.  Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Steven Saltzstein, CEO, Force Family Office. Joining them will be Dr. Mary Spellman, Board Certified, licensed dermatologist who will explore both prevention and next-generation treatment strategies for various forms of skin cancer. </p><p>"We are excited to take part in this fireside chat with Force Family Office," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals. "Dr. Spellman will discuss the future direction of dermatologic oncology and highlight how our INTASYL&#174; siRNA program represents a differentiated and innovative approach to immuno-oncology."</p><p><b>DATE:  Tuesday May 19, 2026</b></p><p><b>TIME:   4 PM EDT</b></p><p><b>REGISTRATION LINK:  </b><a href="https://api.newsfilecorp.com/redirect/DOEy8fPKma"><b>PHIO Pharma - Force Family Office</b></a></p><p><b>Recent Company Highlights</b></p><p>Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. In its Phase 1b trial, Phio has reported that 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events. The Company has also reported a pathological response rate in cSCC across all dosing cohorts of approximately 65%, including an 85% pathological response (6 of 7 patients) in the highest-dose cohort.</p><p>Phio has indicated that FDA engagement regarding next-stage clinical development is targeted for the second quarter of 2026 and has reported cash and cash equivalents projected to sustain operations into the first half of 2027.</p><p><b>About Phio Pharmaceuticals Corp.</b></p><p>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PHIO">PHIO</a>) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL<sup>&#174;</sup> siRNA gene silencing technology to eliminate cancer. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.</p><p>For additional information, visit the Company's website, <a href="https://api.newsfilecorp.com/redirect/rpBXzTw1ym" target="_blank">www.phiopharma.com</a>.  </p><p><b>Forward Looking Statements</b></p><p><i>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements, among other things, regarding the anticipated benefits of our INTASYL&#8482; RNAi platform, the results from our ongoing clinical trials, our expectations that our cash runway will extend into the first half of 2027, our expectations regarding timing of FDA submissions intended to propose and seek guidance for next steps in clinical study design for PH-762, our expectations that such FDA submissions and any related FDA meetings will clarify next steps in advancing the PH-762 development program, details regarding our planned non-clinical toxicology study, and our ability to support ongoing clinical development, operational requirements and strategic initiatives with the capital we currently have on hand, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact of future FDA interactions on the development of our product candidates; the impact to our business and operations by inflationary pressures; recession fears; the development of our product candidates, results from our nonclinical, preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the U.S. Securities and Exchange Commission. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.</i></p><div id="contactInfo"><p><b>Contact:<br />Phio Pharmaceuticals Corp.<br /></b>Jennifer Phillips: <a href="mailto:jphillips@phiopharma.com" target="_blank">jphillips@phiopharma.com<br /></a>Corporate Affairs </p></div><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/10407/296886_2219419cc41d6a03_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/VvjrkfMrXD">https://www.newsfilecorp.com/release/296886</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/296886/197" alt="" /></p>

Phio Pharmaceuticals is participating in an upcoming fireside chat aimed at discussing new strategies in dermatologic oncology, notably featuring its lead candidate PH-762. The strong Phase 1b trial results and scheduled FDA interactions could serve as significant catalysts for the company's stock performance.

Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News